echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Endocrine System > Diabetes: Moristat-an exploration to save the hypoxic response of diabetic heart disease and reverse metabolic dysfunction!

    Diabetes: Moristat-an exploration to save the hypoxic response of diabetic heart disease and reverse metabolic dysfunction!

    • Last Update: 2021-12-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Heart vascular disease is diabetes, cause of death, even with optimal management of risk factors (blood sugar, blood pressure, cholesterol ), the risk of T2D patients suffering from cardiovascular disease is still a 21% increase


    Heart vascular disease is diabetes, cause of death, even with optimal management of risk factors (blood sugar, blood pressure, cholesterol ), the risk of T2D patients suffering from cardiovascular disease is still a 21% increase


    Healthy people researchers induced pluripotent stem cells (of hiPSC) lines IMR90 and cultured in M180 medium mTeSR1 matrix coating plate, separated by ReLeSR


    Healthy people researchers induced pluripotent stem cells (of hiPSC) lines IMR90 and cultured in M180 medium mTeSR1 matrix coating plate, separated by ReLeSR


    The final experimental results show that type 2 diabetes (T2D) damages the activation of hypoxia-inducible factor (HIF) 1a, which is a major transcription factor that can promote the adaptation of cells to hypoxia


    Molidustat stabilizes HIF1a signaling and downstream metabolic adaptation in human cardiomyocytes

    Molidustat stabilizes HIF1a signaling and downstream metabolic adaptation in human cardiomyocytes

    In human cardiomyocytes, molidustat stabilizes HIF1a and downstream HIF target genes, and promotes anaerobic glucose metabolism


    In human cardiomyocytes, molidustat stabilizes HIF1a and downstream HIF target genes, and promotes anaerobic glucose metabolism


    In short, drug stabilization of HIF1a can overcome the slow hypoxia response caused by insulin resistance


    Maria da LuzSousa Fialho ,UjangPurnama ,Kaitlyn MJHDennis ,Claudia N.
    Montes Aparicio ,  Marcos  Castro-Guarda ,  Emmanuelle  Massourides ,  Damian J.
     Tyler ,  Carolyn A.
     Carr ,  Lisa C.
     Heather.
    Maria da Luz  Sousa Fialho Maria da Luz Sousa Fialho MariaSousa Fialho Ujang  Purnama UjangPurnama Kaitlyn MJH  Dennis Kaitlyn MJHDennis Claudia N.
     Montes AparicioClaudia N.
    Montes Aparicio Marcos  Castro-Guarda Marcos Castro-Guarda Emmanuelle  Massourides Emmanuelle Massourides Damian J.
     Tyler Damian J.
    Tyler Carolyn A.
     Carr Carolyn A.
    Carr Lisa C.
     Heather.
    Lisa C.
    Heather.
    Diabetes  2021,  70  (11 )  2518-2531;  DOI:  10.
    2337/db21-0398 DOI:  10.
    2337/db21-0398 DOI: Leave a message here   

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.